利司那肽联合基础胰岛素在既往使用不同胰岛素方案的2型糖尿病患者中的有效性:一项多中心观察性研究  

The Effectiveness of Lixisenatide as an add on Therapy to Basal Insulin in Diabetic Type 2 Patients Previously Treated with Different Insulin Regimes:a Multi-center Observational Study

作　　者：王津京(翻译) 李启富(审校)[2] WANG Jin-jing;LI Qi-fu(Departmend of Endorinology,Fifth Medical Center of Chinese PLA General Hospital,Beijing 100071,China;Departmend of Endorinology,The First Af？liated Hospital of Chongqing Medical University,Chongqing 400016,China)

机构地区：[1]中国人民解放军总医院第五医学中心内分泌科,北京100071 [2]重庆医科大学附属第一医院内分泌科,重庆400016

出　　处：《药品评价》2018年第23期9-11,13,共4页Drug Evaluation

摘　　要：已应用了胰岛素治疗的2型糖尿病患者血糖仍不能达标是糖尿病治疗的难点之一。近期研究发现:新型胰高糖素样肽-1(glucagon-like peptide-1,GLP-1)受体激动剂——利司那肽联合联合基础胰岛素可进一步改善胰岛素治疗效果不好的糖尿病患者的血糖水平。本文通过对2018年5月发表在《糖尿病学与代谢综合征(Diabetology&Metabolic Syndrome)》杂志上的文章"一项利司那肽联合基础胰岛素在既往使用不同胰岛素方案的2型糖尿病患者中的有效性的多中心观察性研究"进行中文摘译;同时,特邀解放军总医院内分泌科母义明教授对此文做一点评。It remains challenging for type 2 diabetic patients previously treated with different insulin regimes and failed in glucose targeting. Recent study had found that a novel glucagon like peptide-1 agonist （Lixisenatide） combined to basal insulin is a choice for the treatment. This combination therapy could further improved glucose control for diabetes uncontrolled by insulin. This article provided simple translation for the research article titled with ＂The effectiveness of lixisenatide as an add on therapy to basal insulin in diabetic type 2 patients previously treated with different insulin regimes a multi-center observational study＂（published in Diabetology ＆ Metabolic Syndrome, 2018 Mar 13, 10： 16） and opinion by invited clinical expert.

关 键 词：利司那肽 胰岛素 2型糖尿病 GLP-1受体激动剂 

分 类 号：R587.1[医药卫生—内分泌]